Halobetasol
Halobetasol propionate is a super-high potency synthetic topical corticosteroid. It possesses anti-inflammatory, antipruritic, and vasoconstrictive properties. Due to its high potency, it is primarily used for short-term treatment of severe skin conditions and requires careful monitoring to prevent systemic side effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression.
Dosage by Body Weight
Apply a thin film to the affected skin areas once or twice daily as directed by a physician. Rub in gently. Limit treatment to 2 consecutive weeks and do not exceed 50 grams per week. Do not use with occlusive dressings unless directed.
- Body Weight
- Below 5 kg
- Dose
- Contraindicated / Not recommended
- Frequency
- Do not use
- Tracking Notes
- Extremely high risk of systemic absorption and adrenal suppression in infants. Safety and efficacy have not been established.
- Body Weight
- 5-7 kg
- Dose
- Contraindicated / Not recommended
- Frequency
- Do not use
- Tracking Notes
- Not recommended for infants. Pediatric patients have a larger skin surface area to body weight ratio, making them more susceptible to systemic toxicity.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Avoid use in toddlers unless specifically prescribed and strictly monitored by a pediatric dermatologist.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Super-high potency topical steroids are generally avoided in young children due to risks of HPA axis suppression and Cushing's syndrome.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Do not use
- Tracking Notes
- Consult a specialist. If absolutely necessary, milder corticosteroids are preferred for pediatric patients under 12 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Contraindicated / Not recommended | Do not use | Extremely high risk of systemic absorption and adrenal suppression in infants. Safety and efficacy have not been established. |
| 5-7 kg | Contraindicated / Not recommended | Do not use | Not recommended for infants. Pediatric patients have a larger skin surface area to body weight ratio, making them more susceptible to systemic toxicity. |
| 8-10 kg | Not recommended | Do not use | Avoid use in toddlers unless specifically prescribed and strictly monitored by a pediatric dermatologist. |
| 11-15 kg | Not recommended | Do not use | Super-high potency topical steroids are generally avoided in young children due to risks of HPA axis suppression and Cushing's syndrome. |
| 16-20 kg | Not recommended | Do not use | Consult a specialist. If absolutely necessary, milder corticosteroids are preferred for pediatric patients under 12 years of age. |
Formulation
Purpose
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as plaque psoriasis and severe eczema.
Generic Name
Halobetasol propionateBranded Drug Names
Halobetasol is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.